Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2011
Probing GABA receptor function in schizophrenia with iomazenil.
Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 42 citations in OpenAlex.
- Role of GABA Deficit in Sensitivity to the Psychotomimetic Effects of Amphetamine.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2015Trial
- GABA Deficits Enhance the Psychotomimetic Effects of Δ9-THC.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2015Trial
- Abnormal GABAergic function and negative affect in schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2014Trial
- Feature binding and detachment in psychosis: A virtual reality study.Schizophrenia research. Cognition · 2025Article
- Investigating the Impacts of Diet, Supplementation, Microbiota, Gut-Brain Axis on Schizophrenia: A Narrative Review.Nutrients · 2024Review
- The Gut-Brain Axis in Schizophrenia: The Implications of the Gut Microbiome and SCFA Production.Nutrients · 2023Review
- Comparison of mouse models reveals a molecular distinction between psychotic illness in PWS and schizophrenia.Translational psychiatry · 2021Article
- Time to re-engage psychiatric drug discovery by strengthening confidence in preclinical psychopharmacology.Psychopharmacology · 2021Review
- The Fragile Brain: Stress Vulnerability, Negative Affect and GABAergic Neurocircuits in Psychosis.Schizophrenia bulletin · 2019Review
- PV Interneurons: Critical Regulators of E/I Balance for Prefrontal Cortex-Dependent Behavior and Psychiatric Disorders.Frontiers in neural circuits · 2018Review
- Gamma band oscillations: a key to understanding schizophrenia symptoms and neural circuit abnormalities.Current opinion in psychiatry · 2016Review
- Impaired prefrontal synaptic gain in people with psychosis and their relatives during the mismatch negativity.Human brain mapping · 2016Article
- The early identification of psychosis: can lessons be learnt from cardiac stress testing?Psychopharmacology · 2016Review
- Altered SPECT (123)I-iomazenil Binding in the Cingulate Cortex of Children with Anorexia Nervosa.Frontiers in psychiatry · 2016Article
- Puzzle Pieces: Neural Structure and Function in Prader-Willi Syndrome.Diseases (Basel, Switzerland) · 2015Review
- GABA abnormalities in schizophrenia: a methodological review of in vivo studies.Schizophrenia research · 2015Review
- In vivo assessment of neurotransmitters and modulators with magnetic resonance spectroscopy: application to schizophrenia.Neuroscience and biobehavioral reviews · 2015Review
- Drug models of schizophrenia.Therapeutic advances in psychopharmacology · 2015Review
- Modulation of GABAergic transmission in development and neurodevelopmental disorders: investigating physiology and pathology to gain therapeutic perspectives.Frontiers in cellular neuroscience · 2014Review
- The influence of NMDA and GABA(A) receptors and glutamic acid decarboxylase (GAD) activity on attention.Psychopharmacology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several lines of evidence from post-mortem, brain imaging, and genetic studies in schizophrenia patients suggest that Gamma-amino butyric acid (GABA) deficits may contribute to the pathophysiology of schizophrenia. Pharmacological induction of a transient GABA-deficit state has been shown to enhance vulnerability of healthy subjects to the psychotomimetic effects of various drugs. Exacerbating or creating a GABA deficit was hypothesized to induce or unmask psychosis in schizophrenia patients, but not in healthy controls. To test this hypothesis, a transient GABA deficit was pharmacologically induced in schizophrenia patients and healthy controls using iomazenil, an antagonist and partial inverse agonist of the benzodiazepine receptor. In a double-blind, randomized, placebo-controlled study, clinically stable chronic schizophrenia patients (n=13) received iomazenil (3.7 μg administered intravenously over 10 min). Psychosis was measured using the Brief Psychiatric Rating Scale and perceptual alterations were measured using the Clinician Administered Dissociative Symptoms Scale before and after iomazenil administration. These data were compared with the effects of iomazenil in healthy subjects (n=20). Iomazenil produced increases in psychotic symptoms and perceptual alterations in schizophrenia patients, but not in healthy controls. The greater vulnerability of schizophrenia patients to the effects of iomazenil relative to controls provides further support for the GABA-deficit hypothesis of schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.